<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117986</url>
  </required_header>
  <id_info>
    <org_study_id>SA13I20317</org_study_id>
    <nct_id>NCT02117986</nct_id>
  </id_info>
  <brief_title>Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients</brief_title>
  <official_title>Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Barros Luco Trudeau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo Nacional de Desarrollo Científico y Tecnológico, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Barros Luco Trudeau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that the loading dose of intravenous colistin (6 million of
      international units) is associated with greater clinical and microbiological efficacy, and
      reduced mortality of critically ill patients infected by multidrug resistant Gram- negative
      bacilli, compared to a scheme without loading dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, multicenter, randomized, controlled study to evaluate a scheme with and
      without a loading dose of 6 million international units of colistin, followed by a
      maintenance dose of 3 million international units every 8 hours intravenous. The study should
      be conducted in 3 hospitals in Chile, in critically patients presenting infection by
      multidrug Gram-negative bacteria and requiring be treated with colistin for at least 48
      hours. The objectives of the study are: to evaluate the clinical and microbiological
      response, and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with clinical response to treatment</measure>
    <time_frame>up to 1 week</time_frame>
    <description>remission or reduction of clinical signs of infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of patients with microbiological response</measure>
    <time_frame>up to 1 week</time_frame>
    <description>negative culture at the same site where the positive culture was obtained before</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>during their stay in the intensive care unit</time_frame>
    <description>the mortality during their stay in the intensive care unit, an expected average of 4 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gram Negative Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>loading dose of colistin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without loading dose of colistin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 million international units of colistin every 8 hours intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colistin</intervention_name>
    <description>One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.</description>
    <arm_group_label>loading dose of colistin</arm_group_label>
    <arm_group_label>without loading dose of colistin</arm_group_label>
    <other_name>colistimethate sodium</other_name>
    <other_name>polymyxin e</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient hospitalized in critical care units

          -  patient infected by multi drug resistant Gram negative bacteria susceptibly only to
             colistin

          -  source of infection: blood, respiratory, intra abdominal or urinary

        Exclusion Criteria:

          -  pregnant or breastfeeding patients

          -  patient with a history of hypersensitivity to colistin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loreto Rojas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Barros Luco Trudeau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Loreto Rojas, MD</last_name>
    <phone>56-9-68479281</phone>
    <email>rojasloreto@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Rosales, PharmD</last_name>
    <phone>56-9-95093184</phone>
    <email>ruth.rosales@vtr.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Barros Luco Trudeau</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8900085</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loreto Rojas, MD</last_name>
      <phone>56-9-68479281</phone>
      <email>rojasloreto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Rosales, PharmD</last_name>
      <phone>56-9-9093184</phone>
      <email>ruth.rosales@vtr.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ruth Rosales, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis Castro, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Pauramani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loreto Rojas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheyla Jimenez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sofía Palma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Beltrán, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Puerto Montt</name>
      <address>
        <city>Puerto Montt</city>
        <zip>5507798</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loreto Rojas, PhD</last_name>
      <phone>+56968479281</phone>
      <email>rojasloreto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Susana Hernandez, Pharm</last_name>
      <phone>+56976373749</phone>
      <email>shernandez@ssdr.gob.cl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critically ill patients</keyword>
  <keyword>colistin dosing</keyword>
  <keyword>multidrug resistant bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

